Expertise in
24
conditions

Dr. James I. Geller

Hematology | Oncology
Rady Children's Hospital San Diego
3020 Childrens Way, 
San Diego, CA 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Expertise in
24
conditions
Rady Children's Hospital San Diego
3020 Childrens Way, 
San Diego, CA 

Overview

James Geller is a Hematologist and an Oncologist practicing medicine in San Diego, California.

Dr. Geller is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Wilms Tumor, Hepatoblastoma, Renal Cell Carcinoma (RCC), Nephrectomy, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 225 peer reviewed articles and participating in 37 clinical trials. Dr. Geller is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in OH

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Health
  • HMO
  • PPO

Locations

Rady Children's Hospital San Diego
3020 Childrens Way, San Diego, CA 92123
Other Locations
Cincinnati Children's Hospital Medical Center
3333 Burnet Ave, Cincinnati, OH 45229

Additional Areas of Focus

Dr. Geller has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

35 Clinical Trials

A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Procedure, Biological, Drug, Other
Study Drugs: Bleomycin, Bleomycin Sulfate, Carboplatin, Cisplatin, Etoposide, Etoposide Phosphate
Study Phase: Phase 3
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Radiation, Drug, Procedure
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin, Etoposide, Ifosfamide, Irinotecan, Topotecan, Vincristine
Study Phase: Phase 2
A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Biological
Study Drugs: Axitinib, Nivolumab
Study Phase: Phase 2
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Other
Study Drugs: Cabozantinib, Cabozantinib-S-Malate
Study Phase: Phase 2
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Other, Procedure
Study Drugs: Carboplatin, Cisplatin, Doxorubicin, Etoposide, Fluorouracil, Gemcitabine, Irinotecan, Oxaliplatin, Sorafenib, Vincristine Sulfate
Study Phase: Phase 3
Pilot Pharmacokinetic Study of VAL-413 (Orotecan®) in Patients With Recurrent Pediatric Solid Tumors
Pilot Pharmacokinetic Study of VAL-413 (Orotecan®) in Patients With Recurrent Pediatric Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2026
Intervention Type: Drug
Study Drugs: VAL-413, Temozolomide
Study Phase: Phase 1
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Enrollment Status: Active_not_recruiting
Publish Date: July 24, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Ensartinib, Erdafitinib, Larotrectinib, Olaparib, Palbociclib, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib
Study Phase: Phase 2
A Phase 2 Study of the MEK Inhibitor Trametinib (NSC# 763093) in Children With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
A Phase 2 Study of the MEK Inhibitor Trametinib (NSC# 763093) in Children With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: July 20, 2026
Intervention Type: Procedure, Drug
Study Drug: Trametinib
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2026
Intervention Type: Procedure, Other, Drug
Study Drug: Ensartinib
Study Phase: Phase 2
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
Enrollment Status: Completed
Publish Date: June 30, 2026
Intervention Type: Drug, Other, Procedure
Study Drugs: Cisplatin, Dexrazoxane, Doxorubicin Hydrochloride, Fluorouracil, Irinotecan Hydrochloride, Temsirolimus, Vincristine Sulfate
Study Phase: Phase 3
View 8 Less Clinical Trials

225 Total Publications

Avoiding Cisplatin-Related Hearing Loss, Including Implementing Sodium Thiosulfate as Otoprotectant Into Daily Pediatric Clinical Practice: Proceedings Based on Evidence and Expert Opinion From the Ototoxicity Taskforce of the SIOP Supportive Care Network.
Avoiding Cisplatin-Related Hearing Loss, Including Implementing Sodium Thiosulfate as Otoprotectant Into Daily Pediatric Clinical Practice: Proceedings Based on Evidence and Expert Opinion From the Ototoxicity Taskforce of the SIOP Supportive Care Network.
Journal: Ear and hearing
Published: June 29, 2026
Similar Doctors
Expertise in
10
conditions
Dr. Courtney D. Thornburg
Hematology | Oncology
Expertise in
10
conditions
Dr. Courtney D. Thornburg
Hematology | Oncology
Referral may be required

Office

3010 Childrens Way, 
San Diego, CA 
 (0.1 miles away)
858-966-8035
Languages Spoken:
English
See accepted insurances

Courtney Thornburg is a Hematologist and an Oncologist practicing medicine in San Diego, California. Dr. Thornburg is highly rated in 10 conditions, according to our data. Her clinical expertise encompasses Hemophilia A, Blood Clots, Sickle Cell Disease, Congenital Hemolytic Anemia, and Splenectomy.

Expertise in
4
conditions
Dr. Peter E. Zage
Hematology | Oncology
Expertise in
4
conditions
Dr. Peter E. Zage
Hematology | Oncology
Referral may be required

Rady Children's Hospital San Diego

3020 Childrens Way, 
San Diego, CA 
 (0.1 miles away)
858-966-5811
Languages Spoken:
English
See accepted insurances

Peter Zage is a Hematologist and an Oncologist practicing medicine in San Diego, California. Dr. Zage is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Gliomatosis Cerebri, and Neural Crest Tumor.

Expertise in
7
conditions
Dr. Julie A. Jaffray
Hematology | Oncology
Expertise in
7
conditions
Dr. Julie A. Jaffray
Hematology | Oncology
Referral may be required

Office

3010 Childrens Way, 
San Diego, CA 
 (0.1 miles away)
858-966-5811
Languages Spoken:
English
See accepted insurances

Julie Jaffray is a Hematologist and an Oncologist practicing medicine in San Diego, California. Dr. Jaffray is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Venous Thromboembolism (VTE), Mesenteric Venous Thrombosis, Blood Clots, Von Willebrand Disease (VWD), and Thrombectomy.

Frequently Asked Questions about Dr. James I. Geller

How do I make an appointment with Dr. James I. Geller?

You can book an appointment with Dr. James I. Geller by calling their office at 858-966-5811. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. James I. Geller a top-rated expert for Wilms Tumor?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. James I. Geller is classified as an Elite expert for Wilms Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. James I. Geller specialize in?

While Dr. James I. Geller is a Hematology, they have specific expertise in Wilms Tumor, Hepatoblastoma, and Renal Cell Carcinoma (RCC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. James I. Geller participate in research or clinical trials?

Yes. Dr. James I. Geller has published 225 articles and abstracts on conditions like Wilms Tumor. You can view a list of Dr. James I. Geller's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. James I. Geller accept my insurance?

Dr. James I. Geller accepts most major insurance plans, including Anthem BCBS and CareSource. We recommend calling the office directly at 858-966-5811 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Geller's expertise for a condition
ConditionClose
View All 17 Advanced Conditions
View All 51 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile